Concepts (94)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 8 | 2022 | 254 | 1.640 |
Why?
|
| Fibrinolytic Agents | 7 | 2022 | 56 | 1.080 |
Why?
|
| Tissue Plasminogen Activator | 6 | 2016 | 39 | 0.810 |
Why?
|
| Remote Consultation | 2 | 2016 | 11 | 0.650 |
Why?
|
| Subarachnoid Hemorrhage | 5 | 2019 | 39 | 0.630 |
Why?
|
| Cerebral Hemorrhage | 3 | 2020 | 106 | 0.380 |
Why?
|
| Thrombolytic Therapy | 5 | 2016 | 46 | 0.370 |
Why?
|
| Hospital Mortality | 3 | 2016 | 130 | 0.360 |
Why?
|
| Infarction, Middle Cerebral Artery | 4 | 2014 | 13 | 0.340 |
Why?
|
| Middle Aged | 13 | 2022 | 8508 | 0.280 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 2 | 2019 | 9 | 0.270 |
Why?
|
| Vasospasm, Intracranial | 2 | 2019 | 10 | 0.270 |
Why?
|
| Thrombectomy | 2 | 2017 | 29 | 0.260 |
Why?
|
| Aged | 12 | 2022 | 8704 | 0.260 |
Why?
|
| Time Factors | 6 | 2020 | 1361 | 0.230 |
Why?
|
| Retrospective Studies | 7 | 2022 | 3290 | 0.220 |
Why?
|
| Humans | 20 | 2022 | 25967 | 0.210 |
Why?
|
| Severity of Illness Index | 3 | 2016 | 929 | 0.210 |
Why?
|
| Pandemics | 2 | 2022 | 238 | 0.210 |
Why?
|
| beta-Alanine | 2 | 2012 | 3 | 0.200 |
Why?
|
| Benzimidazoles | 2 | 2012 | 9 | 0.200 |
Why?
|
| Female | 15 | 2021 | 14351 | 0.190 |
Why?
|
| Anticoagulants | 2 | 2012 | 86 | 0.190 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 27 | 0.190 |
Why?
|
| Male | 14 | 2020 | 13984 | 0.180 |
Why?
|
| Tertiary Care Centers | 1 | 2020 | 62 | 0.170 |
Why?
|
| Intracranial Thrombosis | 1 | 2019 | 6 | 0.170 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2016 | 1140 | 0.170 |
Why?
|
| Endocarditis | 1 | 2019 | 6 | 0.170 |
Why?
|
| Atrial Fibrillation | 2 | 2012 | 132 | 0.170 |
Why?
|
| Brain Ischemia | 1 | 2020 | 60 | 0.170 |
Why?
|
| Nervous System Diseases | 1 | 2020 | 115 | 0.160 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 82 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 85 | 0.150 |
Why?
|
| Acute Disease | 2 | 2016 | 189 | 0.150 |
Why?
|
| Cerebral Amyloid Angiopathy | 1 | 2019 | 114 | 0.150 |
Why?
|
| International Normalized Ratio | 2 | 2014 | 18 | 0.140 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2017 | 9 | 0.140 |
Why?
|
| Patient Transfer | 1 | 2017 | 21 | 0.140 |
Why?
|
| Informed Consent | 1 | 2015 | 19 | 0.120 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 287 | 0.120 |
Why?
|
| Cerebral Infarction | 1 | 2016 | 150 | 0.120 |
Why?
|
| Aged, 80 and over | 7 | 2019 | 4661 | 0.120 |
Why?
|
| Renal Dialysis | 1 | 2015 | 107 | 0.120 |
Why?
|
| Reperfusion | 1 | 2014 | 6 | 0.110 |
Why?
|
| Neoplasms | 1 | 2016 | 219 | 0.110 |
Why?
|
| Kidney Failure, Chronic | 1 | 2015 | 151 | 0.110 |
Why?
|
| Brain Edema | 1 | 2013 | 17 | 0.110 |
Why?
|
| Encephalocele | 1 | 2013 | 23 | 0.110 |
Why?
|
| Intracranial Hypertension | 1 | 2013 | 13 | 0.100 |
Why?
|
| Predictive Value of Tests | 3 | 2019 | 457 | 0.090 |
Why?
|
| Risk Factors | 4 | 2019 | 2240 | 0.090 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2020 | 90 | 0.070 |
Why?
|
| Adult | 5 | 2019 | 7351 | 0.070 |
Why?
|
| Young Adult | 3 | 2019 | 1848 | 0.070 |
Why?
|
| Treatment Outcome | 4 | 2017 | 3292 | 0.070 |
Why?
|
| Cerebral Angiography | 2 | 2019 | 35 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2020 | 1646 | 0.050 |
Why?
|
| Vasoconstriction | 1 | 2019 | 15 | 0.040 |
Why?
|
| Computed Tomography Angiography | 1 | 2019 | 28 | 0.040 |
Why?
|
| Syndrome | 1 | 2019 | 73 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 70 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 713 | 0.040 |
Why?
|
| Recurrence | 1 | 2019 | 306 | 0.040 |
Why?
|
| Comorbidity | 1 | 2020 | 466 | 0.040 |
Why?
|
| Sex Factors | 1 | 2019 | 442 | 0.040 |
Why?
|
| Chicago | 1 | 2020 | 841 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 670 | 0.040 |
Why?
|
| Age Factors | 1 | 2019 | 742 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 2017 | 32 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2016 | 117 | 0.030 |
Why?
|
| Adolescent | 1 | 2021 | 2062 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2015 | 21 | 0.030 |
Why?
|
| Ischemic Attack, Transient | 1 | 2015 | 18 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2016 | 287 | 0.030 |
Why?
|
| Fibrinogen | 1 | 2014 | 15 | 0.030 |
Why?
|
| Blood Coagulation Factors | 1 | 2014 | 17 | 0.030 |
Why?
|
| Triage | 1 | 2014 | 21 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2014 | 64 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2014 | 26 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2014 | 50 | 0.030 |
Why?
|
| Urban Population | 1 | 2014 | 143 | 0.030 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2012 | 5 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2012 | 55 | 0.030 |
Why?
|
| Cerebrovascular Circulation | 1 | 2012 | 34 | 0.030 |
Why?
|
| Partial Thromboplastin Time | 1 | 2012 | 4 | 0.030 |
Why?
|
| Platelet Count | 1 | 2012 | 15 | 0.030 |
Why?
|
| Dabigatran | 1 | 2012 | 5 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2012 | 81 | 0.030 |
Why?
|
| Blood Coagulation | 1 | 2012 | 17 | 0.030 |
Why?
|
| ROC Curve | 1 | 2012 | 132 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2014 | 621 | 0.020 |
Why?
|
| Brain | 1 | 2020 | 1642 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2012 | 1815 | 0.020 |
Why?
|